ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
UniCredit

UniCredit (UI439X)

0.00
0.00
(0.00%)
Closed March 15 12:30PM
Most recent streaming
Time Price Size Type Bid Price Ask Price B/S Buy Ind. Total Volume Num Exch.

Your Recent History

Delayed Upgrade Clock
Play Episode
6min
Proactive - Interviews for investors
Pinnacle Silver & Gold eyes near-term production at high-grade El Potrero project in Mexico
Pinnacle Silver & Gold Corp (TSX-V:PINN, OTCQB:NRGOF) president and CEO Robert Archer talked with Proactive's Stephen Gunnion about the company’s latest acquisition, the El Potrero mine in Mexico. Archer explained that the company is focused on fast-tracking the project towards production within two to three years, aiming to build the business through cash flow rather than relying on external markets. El Potrero was previously in production in the late 1980s, with existing underground workings and a 100-ton-per-day processing plant. Archer highlighted that much of the infrastructure remains in place, which should help streamline redevelopment efforts at a relatively low cost. The company plans to rehabilitate the underground workings, conduct systematic sampling, and commence drilling to establish a resource base sufficient to restart production. On the financial side, Pinnacle Silver recently raised $800,000 in a private placement, with plans to secure up to $2–$3 million over the next few years to fully fund the restart. Archer also shared insights from the PDAC conference, noting positive sentiment around metals despite broader economic uncertainties. The company expects a strong news flow this year as exploration and development efforts accelerate. For more updates, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for the latest news. #Mining #Gold #Silver #PinnacleSilver #MexicoMining #ResourceStocks #JuniorMining #GoldInvestment #MiningExploration #PreciousMetals
Proactive - Interviews for investors
Delivra Health expands Dream Water line with 6-count sleep gummies in Canada
Delivra Health Brands CEO Gord Davey joined Steve Darling from Proactive to announce the launch of Dream Water 6-Count Sleep Gummies in the Canadian market. This new product builds on the success of the 60-count Dream Water Gummies, which debuted in Canada in February 2024 and received strong consumer demand. The 6-count version is set to hit distributors, retailers, and e-commerce channels in March 2025. Davey highlighted that this strategic launch is aimed at capturing growth opportunities in the travel and convenience retail sectors, reinforcing Delivra Health’s position as a leading provider of sleep solutions. By offering a smaller, on-the-go format, the company aims to expand its reach to travelers and impulse buyers, broadening accessibility for consumers seeking convenient sleep aids. The momentum behind Dream Water Sleep Gummies continues to build in both Canada and the U.S., with the new 6-count format being distributed nationwide through Delivra Health’s established retail and e-commerce partners. With this expansion, the company is set to further strengthen its footprint in the sleep wellness market. #proactiveinveestors #delivrahealthbrandsinc #tsxv #dhb #otcqb #dhbuf #DreamWater #GlobalExpansion #UAE #MiddleEastMarket #SleepAid #HealthAndWellness #PharmacyProducts #RegulatoryCompliance #DreamWater #SleepGummies #Wellness #SleepAid #TravelEssentials #CanadianRetail #HealthAndWellness #InsomniaRelief #SleepBetter
Proactive - Interviews for investors
Bitwise’s Bradley Duke on the BTCG ETP: gold & Bitcoin combined
Bitwise Asset Management European head Bradley Duke talked with Proactive about Bitcoin’s recent price movements and the company’s latest product launch. Duke discussed the volatility of Bitcoin, noting both its tailwinds—such as increased demand from corporate investors and national reserves—and the headwinds, including geopolitical uncertainties. He pointed out that institutional investors are turning instead to alternative safe-haven assets like gold. The conversation then shifted to Bitwise’s latest product, Bitwise Diaman Bitcoin & Gold ETP (BTCG), which launched today on Euronext in Paris and Amsterdam. Duke explained that the product is a collaboration with Diaman Partners, part of asset manager Azimut. The ETP dynamically allocates between Bitcoin and gold based on an index that considers drawdowns and recovery rates. "We’ve looked at the performance of this index versus the S&P 500, Nasdaq 100, and gold alone, and it has outperformed considerably," said Duke. He emphasised that while past performance is no guarantee of future results, the product arrives at a time when institutions are actively seeking alternative safe-haven assets. For more insights and interviews, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and enable notifications for updates. #Bitcoin #Gold #BTCG #Bitwise #CryptoInvesting #DigitalAssets #SafeHaven #ETP #Investment #Markets
Proactive - Interviews for investors
Lisata Therapeutics expands drug discovery with GATC AI collaboration
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo talked with Proactive about the company’s strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC’s technology, which is recognized by Lloyd’s of London for clinical trial risk assessment, will be used to analyze Lisata’s lead candidate, certepetide, and identify potential new drug combinations. Mazzo highlighted that this collaboration will optimize Lisata’s ongoing cancer research, including trials in pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other cancers. He noted that GATC’s AI technology can perform billions of simulations rapidly, potentially reducing the cost and risk of drug development. Discussing Lisata’s 2025 outlook, Mazzo described it as a "data-rich year," with upcoming results from the ASCEND trial and other studies. He emphasized the potential for certepetide in combination with immunotherapy and the company’s ongoing discussions with regulatory agencies and potential partners. To watch more interviews like this, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #LisataTherapeutics #Biotech #CancerResearch #AIinHealthcare #DrugDevelopment #ClinicalTrials #GATCHealth #Pharma #Oncology #Investing